GlaxoSmithKline plc (ADR) (GSK) Analysts See $0.71 EPS

Share

Stockman Wealth Management Inc. increased its stake in GlaxoSmithKline PLC (NYSE:GSK) by 2.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The stock was bought at an average price of GBX 1,583 ($20.51) per share, for a total transaction of £5,303.05 ($6,869.24).

It also reduced its holding in Exxon Mobil Corp (NYSE:XOM) by 3,765 shares in the quarter, leaving it with 386,360 shares, and cut its stake in Wells Fargo & Co New (NYSE:WFC). Trexquant Investment LP purchased a new position in shares of GlaxoSmithKline PLC during the fourth quarter worth $239,000. The firm has "Buy" rating by Jefferies given on Thursday, July 14. Pekin Singer Strauss Asset Management IL raised its position in GlaxoSmithKline PLC by 1.1% in the first quarter. About 2.37 million shares traded. Heritage Trust Co bought a new stake in shares of GlaxoSmithKline PLC during the first quarter valued at approximately $123,000. Finally, Perigon Wealth Management LLC increased its position in shares of GlaxoSmithKline PLC by 3.3% in the fourth quarter. Westwood Holdings Group Inc. now owns 2,950 shares of the pharmaceutical company's stock valued at $124,000 after buying an additional 400 shares during the last quarter. The SI to Glaxosmithkline Plc's float is 0.2%.

Shares of GlaxoSmithKline plc (LON:GSK) opened at 1608.50 on Friday. The stock's 50 day moving average price is GBX 1,673.22 and its 200 day moving average price is GBX 1,618.58. The company has market cap of $103.49 billion.

GlaxoSmithKline PLC (NYSE:GSK) last posted its quarterly earnings results on Wednesday, April 26th. The institutional investor held 104,390 shares of the major pharmaceuticals company at the end of 2016Q4, valued at $4.02 million, up from 55,360 at the end of the previous reported quarter. GlaxoSmithKline PLC had a return on equity of 113.31% and a net margin of 5.48%. Next quarter's EPS is estimated at $0.81 and the next full year EPS is anticipated to be $2.86.


The company also recently declared a dividend, which was paid on Thursday, July 13th. The ex-dividend date was set for Wednesday the 10th of May 2017. This represents a $1.93 dividend on an annualized basis and a dividend yield of 4.52%. This is an increase from GlaxoSmithKline PLC's previous quarterly dividend of $0.46.

TRADEMARK VIOLATION NOTICE: This article was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another domain, it was illegally copied and reposted in violation of USA and worldwide copyright and trademark law. The correct version of this news story can be read at https://www.com-unik.info/2017/07/16/curbstone-financial-management-corp-reduces-stake-in-glaxosmithkline-plc-nysegsk.html. Visa Inc. had 51 analyst reports since July 21, 2015 according to SRatingsIntel. Berenberg Bank raised shares of GlaxoSmithKline PLC from a "hold" rating to a "buy" rating in a research report on Friday, May 26th. The firm has "Buy" rating given on Monday, December 7 by Argus Research. The firm earned "Neutral" rating on Friday, June 16 by J P Morgan Chase Co. The stock of GlaxoSmithKline plc (ADR) (NYSE:GSK) has "Neutral" rating given on Tuesday, September 8 by Bank of America. Finally, TheStreet raised GlaxoSmithKline PLC from a "c" rating to a "b" rating in a report on Friday, May 19th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and ten have assigned a buy rating to the company's stock. The company now has an average rating of "Hold" and a consensus price target of GBX 1,732.78 ($22.45).

This is a increase from GlaxoSmithKline PLC's prior periodic dividend of $0.46. this indicates a $1.93 annual dividend and a payout of of 4.58%. The Firm operates through three business units: Composite Fibers, Advanced Airlaid Materials and Specialty Papers. The Firm focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus /infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Share